LONDON and PHILADELPHIA , March 10, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful ...

As of March 3 at 3:00:00 PM EST. Market Open. Key Insights Avacta Group's significant individual investors ownership suggests that the key decisions are influenced... Avacta Group Plc ( LON:AVCT ...

Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the ...

ELCC is a program of the European Society for Medical Oncology (ESMO ... M.D., CEO of MAIA. "Our poster features our latest findings on cytokine Interleukin-6 (IL-6) as a potential predictive ...

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts Encouraging Progression Free Survival ...

UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN Avacta Announces Agreement to Sell Launch ...

It’s another standard of excellence in cinema—and we’d argue that there’s indeed correlation between great posters and great films. Consider: In our (admittedly wildly unscientific!) ...

LONDON and PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful ...

Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta Reports Pipeline Advances with Two Novel Programs at the EORTC-NCI-AACR Molecular Targets Symposium in Barcelona LONDON – Oct. 24, ...

Avacta Therapeutics, a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumour payloads directly to the tumour, has agreed to sell Launch ...